Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 4Phase 1 2Phase NA 1Phase 3 1Phase 2/3 1

Status

Completed 5Recruiting 4Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 2Sarcoma, Myeloid 1Leukemia, Hairy Cell 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Capecitabine 27Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Cladribine × Clear all
NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT04797767 2026-04-17

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

University of Washington

Phase 1/2 Recruiting
62 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT06561152 2026-04-14

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Stanford University

Phase 1/2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04047641 2025-12-17

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡